Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the phenylpyrazole class, 1‑Phenylsulfonamide‑3‑Trifluoromethyl‑5‑Parabromophenylpyrazole (also known as SC‑558), is a potent and selective inhibitor of prostaglandin G/H synthase 2 (commonly known as cyclooxygenase‑2 or COX‑2). It is not approved for clinical use but has been widely used in research to study COX‑2 inhibition. The compound exhibits high selectivity for COX‑2 over COX‑1, with an IC50 value of approximately 9.3 nM for COX‑2 inhibition[2][3]. Its primary application is in experimental pharmacology and biochemistry as a tool compound to investigate inflammatory pathways mediated by prostaglandins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-Phenylsulfonamide-3-Trifluoromethyl-5-Parabromophenylpyrazole.